Scientific Reports (Jan 2022)

Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions

  • Nishi Karunasinghe,
  • Tsion Zewdu Minas,
  • Bo-Ying Bao,
  • Arier Lee,
  • Alice Wang,
  • Shuotun Zhu,
  • Jonathan Masters,
  • Megan Goudie,
  • Shu-Pin Huang,
  • Frank J. Jenkins,
  • Lynnette R. Ferguson

DOI
https://doi.org/10.1038/s41598-021-04116-8
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 16

Abstract

Read online

Abstract It is being debated whether prostate-specific antigen (PSA)-based screening effectively reduces prostate cancer mortality. Some of the uncertainty could be related to deficiencies in the age-based PSA cut-off thresholds used in screening. Current study considered 2779 men with prostate cancer and 1606 men without a cancer diagnosis, recruited for various studies in New Zealand, US, and Taiwan. Association of PSA with demographic, lifestyle, clinical characteristics (for cases), and the aldo–keto reductase 1C3 (AKR1C3) rs12529 genetic polymorphisms were analysed using multiple linear regression and univariate modelling. Pooled multivariable analysis of cases showed that PSA was significantly associated with demographic, lifestyle, and clinical data with an interaction between ethnicity and age further modifying the association. Pooled multivariable analysis of controls data also showed that demographic and lifestyle are significantly associated with PSA level. Independent case and control analyses indicated that factors associated with PSA were specific for each cohort. Univariate analyses showed a significant age and PSA correlation among all cases and controls except for the US-European cases while genetic stratification in cases showed variability of correlation. Data suggests that unique PSA cut-off thresholds factorized with demographics, lifestyle and genetics may be more appropriate for prostate cancer screening.